Namandje Bumpus insider trades: Recursion Pharmaceuticals (RXRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Namandje reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | RXRX | ↓ Sell | 3,963 | $3.18 | $13K | Direct | Jun 22, 2026 (4d) |
| Jun 3, 2026 | RXRX | ↓ Sell | 4,386 | $3.54 | $16K | Direct | Jun 4, 2026 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RXRX insiders
Open-market trades in the last 12 months
About Namandje Bumpus's insider trades
Namandje Bumpus is a director at Recursion Pharmaceuticals (RXRX). Since Jun 3, 2026, Namandje has reported no open-market purchases and 2 sales worth $28K on SEC Form 4. In the last 12 months: 2 sales ($28K).
Their filings also include grants and awards (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RXRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.